Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Liabilities and Shareholders Equity data on record, last reported at $160.5 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 27.17% year-over-year to $160.5 million; the TTM value through Dec 2025 reached $723.2 million, down 1.98%, while the annual FY2025 figure was $160.5 million, 27.17% down from the prior year.
  • Liabilities and Shareholders Equity reached $160.5 million in Q4 2025 per ACRS's latest filing, down from $175.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $288.0 million in Q2 2021 and bottomed at $160.5 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $216.7 million, with a median of $219.3 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 266.46% in 2021, then tumbled 31.65% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $251.2 million in 2021, then increased by 1.35% to $254.6 million in 2022, then dropped by 22.46% to $197.4 million in 2023, then increased by 11.61% to $220.3 million in 2024, then dropped by 27.17% to $160.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $160.5 million in Q4 2025, $175.5 million in Q3 2025, and $189.1 million in Q2 2025.